Cantargia strengthens management with a Vice President Clinical Development

Lars Thorsson has been appointed Vice President Clinical Development of Cantargia AB. Lars Thorsson graduated with a Ph.D. in clinical pharmacology in 1998 and has more than 25 years’ experience from the pharmaceutical industry, including leading roles in project management and clinical studies in most development phases at AstraZeneca. Before joining Cantargia, Lars Thorsson worked at Novo Nordisk A/S, where he held the role of Senior Clinical Pharmacology Scientist with responsibility for preparation and implementation of clinical pharmacological studies in development projects. He has also been responsible for evaluation as well as documentation of new substances and has experience of regulatory activities and contacts with authorities.

Lars Thorsson will take up the position as VP Clinical Development at Cantargia on June 1 2015.

“We are very pleased to have succeeded with the recruitment of Lars Thorsson. He has a long, international experience of leading projects in clinical phases. The recruitment of Lars Thorsson is important and takes place at a time when we are planning for coming clinical studies,” says Göran Forsberg, CEO of Cantargia.

Certified Adviser

Sedermera Fondkommission is the company’s Certified Adviser.

For further information, please contact

Göran Forsberg, CEO
Telephone: +46 46 275 62 60
E-mail: goran.forsberg@cantargia.com

wkr0006.pdf